San Francisco, The Palace Hotel, BIO Investor Forum meeting, Tues. Oct. 7, 2014. The annual BIO Investor Forum opened its meeting at midday with welcome remarks and a program change that included new information about the urgent subject about healthcare developments in Ebola among other topics. The welcome remarks featured a short discussion with Tekmira Pharmaceuticals’ CEO, Dr. Mark Murray PhD about his firm’s involvement in this fast moving healthcare area. Dr. Murray touched on the fact that Tekmira is working on a promising early stage antiviral drug to treat patients infected by the ebola virus. More details would follow at his afternoon investor talk
Dr. Murray said in his afternoon investor talk that Tekmira Pharmaceuticals uses an RNA interference based therapeutic in their ebola drug development program. RNA interference (RNAi) is a naturally occurring internal cellular process that shuts down the production of targeted proteins. Dr. Mark Murray also talked about Tekmira’s drug therapy developments in nine clinical programs underway. He said that Tekmira can trigger RNAi, but needs a delivery technology that uses the LNP-RNAi trigger mechanism. They are working on the TKM-PLK1, TKM-H8v, TKM-ebola drug programs. The firm is using the FDA orphan drug rare disease designation for HTG, GSD4 and so on. Their Lipid NanoParticle (LNP) partner, is Anylum, using their ALN-TTR02 platform.
Tekmira has nine products in its clinical pipeline. Dr. Murray said that its lead products include two antiviral programs. The TKM-HBV is being developed to treat Hepatitis B and is being readied for sometime in 2015. The TKM-Ebola program is in phase 1 clinical testing. The FDA gave Tekmira a‘Fast track’ designation for the program. Dr. Murray added that the product formulation gave a very high survival result in animal testing using monkeys. Tekmira will work with the World Health Organization (WHO) in the West African region for its ebola drug human clinical testing program.
Oncology product programs. The TEK-PLK1 product acts on pololukekine-1, which is found in many tumor types, usually ones linked to poor outcomes. The tumor types include GI neuroendochrine tumor and adenocortico cancer.
Rare disease program. Hyper trigliceridemia. The condition leads to pancreatitis. GSD glycogen is a rare condition.
Financials. Tekmira Pharmaceuticals (TKMR) is a public stock company located in Toronto, Canada, is on the NASDAQ stock Exchange and has a $528Million market cap.
Drug Program Status.
- 2014 PLK1 Phase I/II
- 2015 Follow on of clinic activity.
Dr. Murray concluded his talk by saying that for further information go to the company website at email@example.com.
Several hundred investors and presenting company officials gathered at this year’s BIO Investor Forum meeting for one-on-one partnering meetings, 128 company presentations, plenary informational talks, workshops and networking.